Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 6, 2009, Pages 850-856

  Liu, Jing ^a   Zhang, Hongqi ^a,b   Li, Zhiqiang ^a   Hailemariam, Tiruneh K ^a   Chakraborty, Mahua ^a   Jiang, Kailiu ^a   Qiu, Daniel ^a   Bui, Hai H ^c   Peake, David A ^c   Kuo, Ming Shang ^c   Wadgaonkar, Raj ^a   Cao, Guoqing ^c   Jiang, Xian Cheng ^a,d  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b FUDAN UNIVERSITY   (China)

^c ELI LILLY AND COMPANY   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Plasma cholesterol; Plasma lipoproteins; Plasma sphingomyelin; SMS2 knockout mice; SMS2 liver specific transgenic mice

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; ENZYME; LIPOPROTEIN; PHOSPHOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN SYNTHASE 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; NERVE PROTEIN; PHOSPHATIDYLCHOLINE CERAMIDE PHOSPHOCHOLINE TRANSFERASE; PHOSPHATIDYLCHOLINE-CERAMIDE PHOSPHOCHOLINE TRANSFERASE; PHOSPHOTRANSFERASE; SGMS1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE; GENE FUNCTION; GENE OVEREXPRESSION; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; ENZYMOLOGY; FAT INTAKE; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHOLESTEROL; DIETARY FATS; HUMANS; LIPOPROTEINS; LIVER; MACROPHAGES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS; TRANSFERASES (OTHER SUBSTITUTED PHOSPHATE GROUPS);

EID: 66349128899     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.185223     Document Type: Article

References (36)

1. Phillips GB, Dodge JT. Composition of phospholipids and of phospholipid fatty acids of human plasma. J Lipid Res. 1967;8:676-681.
2. Subbaiah PV, Davidson MH, Ritter MC, Buchanan W, Bagdade JD. Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. Atherosclerosis. 1989;79:157-166.
3. Rodriguez AL, Ghiselli GC, Torreggiani D, Sirtori CR. Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism. Part 1: chemical composition of very low density lipoprotein in rabbits. Atherosclerosis. 1976;23:73-83.
4. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low density lipoprotein. J Clin Invest. 1996; 98:1455-1464.
5. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
6. Jeong T-S, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang XC. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest. 1998;101:905-912.
7. Plump AS, Breslow JL. Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr. 1995;15:495-518.
8. Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, Lu S, Jiang XC. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem. 2005;280:10284-10289.
9. Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2004;110:3465-3471.
10. Li Z, Basterr MJ, Hailemariam TK, Hojjati MR, Lu S, Liu J, Liu R, Zhou H, Jiang XC. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim Biophys Acta. 2005; 1735:130-134.
11. Jiang XC, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, Berglund L, Tall AR. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20:2614-2618.
12. Schlitt A, Blankenberg S, Yan D, von Gizycki H, Buerke M, Werdan K, Bickel C, Lackner KJ, Meyer J, Rupprecht HJ, Jiang XC. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr Metab. 2006;3:5-12.
13. Merrill AH, Jones DD. An update of the enzymology and regulation sphingomyelin metabolism. Biochim Biophysi Acta. 1990;1044:1-12.
14. Hamilton RL, Moorehouse A, Havel RJ. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J Lipid Res. 1991;32:529-543.
15. Nisson A. The presence of sphingomyelin and ceramide-cleaving enzymes in the intestinal tract of the rat. Biochim Biophys Acta. 1969; 176:339-347.
16. Nilsson A, Duan RD. Absorption and lipoprotein transport of sphingomyelin. J Lipid Res. 2006;47:154-171.
17. Huitema K, van den Dikkenberg J, Brouwers JF, Holthuis JC. Identification of a family of animal sphingomyelin synthases. EMBO J. 2004; 23:33-44.
18. Li Z, Hailemariam TK, Zhou H, Li Y, Duckworth DC, Peake DA, Zhang Y, Kuo MS, Cao G, Jiang XC. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. Biochim Biophys Acta. 2007;1771: 1186-1194.
19. Miyaji M, Jin ZX, Yamaoka S, Amakawa R, Fukuhara S, Sato SB, Kobayashi T, Domae N, Mimori T, Bloom ET, Okazaki T, Umehara H. Role of membrane sphingomyelin and ceramide in platform formation for Fas-mediated apoptosis. J Exp Med. 2005;202:249-259.
20. Van der Luit AH, Budde M, Zerp S, Caan W, Klarenbeek JB, Verheij M, Van Blitterswijk WJ. Resistance to alkyl-lysophospholipid-induced apoptosis due to downregulated sphingomyelin synthase 1 expression with consequent sphingomyelin- and cholesterol-deficiency in lipid rafts. Biochem J. 2007;401:541-549.
21. Hailemariam TK, Huan C, Liu J, Li Z, Roman C, Kalbfeisch M, Bui HH, Peake DA, Kuo MS, Cao G, Wadgaonkar R, Jiang XC. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation. Arterioscler Thromb Vasc Biol. 2008;28:1519-1526.
22. Fan J, Wang J, Bensadoun A, Lauer SJ, Dang Q, Mahley RW, Taylor JM. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proc Natl Acad Sci USA. 1994;91:8724-8728.
23. Hojjati MR, Jiang XC. Rapid, specific, and sensitive measurements of plasma sphingomyelin and phosphatidylcholine. J Lipid Res. 2006;47: 673-676.
24. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest. 1999;103:907-914.
25. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101:689-695.
26. Ishitsuka R, Yamaji-Hasegawa A, Makino A, Hirabayashi Y, Kobayashi T. A lipid-specific toxin reveals heterogeneity of sphingomyelin-containing membranes. Biophys J. 2004;86:296-307.
27. Innerarity TL, Pitas RE, Mahley RW. Modulating effects of canine high density lipoproteins on cholesteryl ester synthesis induced by β-very low density lipoproteins in macrophages. Possible in vitro correlates with atherosclerosis. Arteriosclerosis. 1982;2:114-124.
28. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-1844.
29. Dong J, Liu J, Lou B, Li Z, Ye X, Wu M, Jiang XC. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J Lipid Res. 2006;47:1307-1314.
30. Simons K, Ikonen E. Functional rafts in cell membranes. Nature. 1997; 387:569-572.
31. Lucic D, Huang ZH, Gu D, Subbaiah PV, Mazzone T. Cellular sphingolipids regulate macrophage apolipoprotein E secretion. Biochemistry. 2007;46:11196-11204.
32. Gkantiragas I, Brugger B, Stuven E, Kaloyanova D, Li XY, Lohr K, Lottspeich F, Wieland FT, Holms JB. (2001) Sphingomyelin-enriched microdomains at the Golgi complex. Mol Biol Cell. 2001;12:1819-1833.
33. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry. 2001;40: 4893-4903.
34. Grassmé H, Jekle A, Riehle A, Schwa H, Berge J, Sandhoff K, Kolesnick R, Gulbins E. CD95 signaling via ceramide-rich membrane rafts. J Biol Chem. 2001;276:20589-20596.
35. Mahley RW, Huang Y, Weisgraber KH. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest. 2006;116: 1226-1229.
36. Nagao K, Takahashi K, Hanada K, Kioka N, Matsuo M, Ueda K. Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells. J Biol Chem. 2007; 282:14868-14874.